Certara Appoints Rosemary Crane as New Independent Board Member
July 25 2022 - 8:00AM
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,
today announced the appointment of Rosemary Crane to its Board of
Directors, effective July 21, 2022. Her appointment brings the
company’s board of directors to eleven members.
“We are excited to welcome an accomplished business leader with
a proven track record of success join Certara’s Board,” said
William F. Feehery, PhD, CEO of Certara. “Rose’s experience in
executive leadership and expertise in commercialization will
provide immense value as the Company grows its impact on the
biopharmaceutical industry worldwide.”
Ms. Crane has more than 35 years of experience in the
pharmaceutical and healthcare industries. She was President and
Chief Executive Officer of MELA Sciences and previously, she was
Partner and Head of Commercialization at Appletree Partners. Ms.
Crane also served as President and Chief Executive Officer of
Epocrates, where she led a successful IPO. Prior to that, she held
various senior executive positions at Johnson & Johnson,
including as Group Chairman, OTC & Nutritional Group and Group
Chairman, Consumer, Specialty Pharmaceuticals and Nutritionals.
Earlier in her career, Ms. Crane spent 20 years at Bristol-Myers
Squibb, including as President of U.S. Primary Care.
“I am pleased to join Certara’s Board of Directors and bring my
broad operational experience across the pharmaceutical industry to
a company that is tackling some of the toughest challenges in drug
discovery and development,” said Ms. Crane. “I look forward to
working with the other board members and Certara’s leadership team
to advance the Company’s next phase of growth.”
Ms. Crane currently serves on the Board of Directors for Tarsus
Pharmaceuticals (Nasdaq: TARS), Catalent Pharma Solutions (NYSE:
CTLT) and Teva Pharmaceuticals (NYSE: TEVA). She is also the Vice
Chairman of the Foundation Board at State University of New York at
Oswego.
About Certara Certara accelerates medicines
using proprietary biosimulation software, technology and services
to transform traditional drug discovery and development. Its
clients include more than 2,000 biopharmaceutical companies,
academic institutions, and regulatory agencies across 62
countries.
Certara ContactJieun W.
Choejieun.choe@certara.com
Investor Relations ContactDavid
Deuchlerir@certara.com
Media ContactAriane LovellFinn
Partnersariane.lovell@finnpartners.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Sep 2023 to Sep 2024